Clinical trial NCT00431067: Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Official title: Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Neoplasms
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2007-02-05
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metastatic breast cancer patients after failure of trastuzumab containing regimens.


Eligibility criteria: Inclusion criteria:

Inclusion Criteria:

1. Male or female patients with confirmed diagnosis of Stage IIIB or IV HER2-positive metastatic breast cancer(HER2 2+ and FISH positive or HER2 3+).
2. Patients must have progressed following receipt of prior standard trastuzumab treatment or standard chemotherapy in conjunction with trastuzumab. Patients with visceral disease or rapid progression should not be included if they have not had previous chemotherapy in addition to trastuzumab. Patients who are intolerant to trastuzumab and who have received adequate chemotherapy and/or hormone therapy are eligible upon progression.
3. Age 18 years or older.
4. Life expectancy of at least four (4) months.
5. Written informed consent that is consistent with ICH-GCP guidelines.
6. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance Score 0, 1 or 2.
7. Patients should not have received treatment with chemotherapy or immune therapy within the last 4 weeks (2 weeks for trastuzumab). Patients should not have received treatment with hormone therapy within the last 2 weeks.
8. Patients must have recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies to CTC less than or equal to Grade 1.
9. Patients must have recovered from previous surgery.
10. Patients must have measurable disease as defined by RECIST criteria.

Exclusion criteria:

Exclusion Criteria:

1. Active infectious disease.
2. Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea.
3. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol.
4. Patients with active/symptomatic brain metastases. Patients with a history of treated brain metastases must have stable or normal MRI scan at screening and be at least three months post-radiation or surgery.
5. Cardiac left ventricular function with resting ejection fraction \<50%.
6. Absolute neutrophil count (ANC) less than 1500 cells/mm3.
7. Platelet count less than 100 000 cells/mm3.
8. Bilirubin greater than 1.5 mg/dl (\>26 micromol /L, SI unit equivalent).
9. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal.
10. Serum creatinine greater than 1.5 mg/dl (\>132 micromol/L, SI unit equivalent).
11. Women and men (and their partners) who are sexually active and unwilling to use a medically acceptable method of contraception.
12. Pregnancy or breast-feeding.
13. Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy or hormone therapy (including LHRH agonists, or other hormones taken for breast cancer), or participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study. Treatment with bisphosphonates is allowed.
14. Prior treatment with an EGFR- or HER2 inhibiting drug (except trastuzumab).
15. Patients unable to comply with the protocol.
16. Active alcohol or drug abuse.
17. Patients with history of other malignancy (except for appropriately treated superficial basal cell skin cancer and surgically cured cervical cancer in situ) unless free of disease for at least 3 years.

Primary outcomes:
measure: Objective Response (OR)
timeFrame: From first dose of study medication to response measurement, up to 34 month
Secondary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: From first dose of study medication to the occurrence of progression or death whichever came first, up to 34 month
measure: Overall Survival (OS)
timeFrame: From first dose of study medication to death or to the last date the patient was known to be alive, up to 34 month
measure: Time to RECIST Tumour Reponse
timeFrame: From first dose of study medication to time when OR measurement was taken.
measure: Duration of Confirmed OR
timeFrame: From first OR to time of progression or death
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: 1200.11.3 Boehringer Ingelheim Investigational Site
state: Arizona
city: Encinitas
country: United States
facility: 1200.11.7 Boehringer Ingelheim Investigational Site
state: California
city: Santa Monica
country: United States
facility: 1200.11.4 Boehringer Ingelheim Investigational Site
state: California
city: Tampa
country: United States
facility: 1200.11.2 Boehringer Ingelheim Investigational Site
state: Florida
city: Boston
country: United States
facility: 1200.11.1 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Chapel Hill
country: United States
facility: 1200.11.5 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Bournemouth
country: United Kingdom
facility: 1200.11.4401 Boehringer Ingelheim Investigational Site
city: Crownhill, Plymouth
country: United Kingdom
facility: 1200.11.4402 Boehringer Ingelheim Investigational Site
city: Guildford
country: United Kingdom
facility: 1200.11.4406 Boehringer Ingelheim Investigational Site
city: London
country: United Kingdom
facility: 1200.11.4405 Boehringer Ingelheim Investigational Site
city: Poole
country: United Kingdom
facility: 1200.11.4404 Boehringer Ingelheim Investigational Site
city: Truro
country: United Kingdom
facility: 1200.11.4403 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References: